Cargando…
Inhibition of autophagy enhances the selective anti-cancer activity of tigecycline to overcome drug resistance in the treatment of chronic myeloid leukemia
BACKGROUND: Drug resistance and disease progression are still the major obstacles in the treatment of chronic myeloid leukemia (CML). Increasing researches have demonstrated that autophagy becomes activated when cancer cells are subjected to chemotherapy, which is involved in the development of drug...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5345227/ https://www.ncbi.nlm.nih.gov/pubmed/28283035 http://dx.doi.org/10.1186/s13046-017-0512-6 |
_version_ | 1782513674324279296 |
---|---|
author | Lu, Ziyuan Xu, Na He, Bolin Pan, Chengyun Lan, Yangqing Zhou, Hongsheng Liu, Xiaoli |
author_facet | Lu, Ziyuan Xu, Na He, Bolin Pan, Chengyun Lan, Yangqing Zhou, Hongsheng Liu, Xiaoli |
author_sort | Lu, Ziyuan |
collection | PubMed |
description | BACKGROUND: Drug resistance and disease progression are still the major obstacles in the treatment of chronic myeloid leukemia (CML). Increasing researches have demonstrated that autophagy becomes activated when cancer cells are subjected to chemotherapy, which is involved in the development of drug resistance. Therefore, combining chemotherapy with inhibition of autophagy serves as a new strategy in cancer treatment. Tigecycline is an antibiotic that has received attention as an anti-cancer agent due to its inhibitory effect on mitochondrial translation. However, whether combination of tigecycline with inhibition of autophagy could overcome drug resistance in CML remains unclear. METHODS: We analyzed the biological and metabolic effect of tigecycline on CML primary cells and cell lines to investigate whether tigecycline could regulate autophagy in CML cells and whether coupling autophagy inhibition with treatment using tigecycline could affect the viabilities of drug-sensitive and drug-resistant CML cells. RESULTS: Tigecycline inhibited the viabilities of CML primary cells and cell lines, including those that were drug-resistant. This occurred via the inhibition of mitochondrial biogenesis and the perturbation of cell metabolism, which resulted in apoptosis. Moreover, tigecycline induced autophagy by downregulating the PI3K-AKT-mTOR pathway. Additionally, combining tigecycline use with autophagy inhibition further promoted the anti-leukemic activity of tigecycline. We also observed that the anti-leukemic effect of tigecycline is selective. This is because the drug targeted leukemic cells but not normal cells, which is because of the differences in the mitochondrial biogenesis and metabolic characterization between the two cell types. CONCLUSIONS: Combining tigecycline use with autophagy inhibition is a promising approach for overcoming drug resistance in CML treatment. |
format | Online Article Text |
id | pubmed-5345227 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-53452272017-03-14 Inhibition of autophagy enhances the selective anti-cancer activity of tigecycline to overcome drug resistance in the treatment of chronic myeloid leukemia Lu, Ziyuan Xu, Na He, Bolin Pan, Chengyun Lan, Yangqing Zhou, Hongsheng Liu, Xiaoli J Exp Clin Cancer Res Research BACKGROUND: Drug resistance and disease progression are still the major obstacles in the treatment of chronic myeloid leukemia (CML). Increasing researches have demonstrated that autophagy becomes activated when cancer cells are subjected to chemotherapy, which is involved in the development of drug resistance. Therefore, combining chemotherapy with inhibition of autophagy serves as a new strategy in cancer treatment. Tigecycline is an antibiotic that has received attention as an anti-cancer agent due to its inhibitory effect on mitochondrial translation. However, whether combination of tigecycline with inhibition of autophagy could overcome drug resistance in CML remains unclear. METHODS: We analyzed the biological and metabolic effect of tigecycline on CML primary cells and cell lines to investigate whether tigecycline could regulate autophagy in CML cells and whether coupling autophagy inhibition with treatment using tigecycline could affect the viabilities of drug-sensitive and drug-resistant CML cells. RESULTS: Tigecycline inhibited the viabilities of CML primary cells and cell lines, including those that were drug-resistant. This occurred via the inhibition of mitochondrial biogenesis and the perturbation of cell metabolism, which resulted in apoptosis. Moreover, tigecycline induced autophagy by downregulating the PI3K-AKT-mTOR pathway. Additionally, combining tigecycline use with autophagy inhibition further promoted the anti-leukemic activity of tigecycline. We also observed that the anti-leukemic effect of tigecycline is selective. This is because the drug targeted leukemic cells but not normal cells, which is because of the differences in the mitochondrial biogenesis and metabolic characterization between the two cell types. CONCLUSIONS: Combining tigecycline use with autophagy inhibition is a promising approach for overcoming drug resistance in CML treatment. BioMed Central 2017-03-10 /pmc/articles/PMC5345227/ /pubmed/28283035 http://dx.doi.org/10.1186/s13046-017-0512-6 Text en © The Author(s). 2017 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
spellingShingle | Research Lu, Ziyuan Xu, Na He, Bolin Pan, Chengyun Lan, Yangqing Zhou, Hongsheng Liu, Xiaoli Inhibition of autophagy enhances the selective anti-cancer activity of tigecycline to overcome drug resistance in the treatment of chronic myeloid leukemia |
title | Inhibition of autophagy enhances the selective anti-cancer activity of tigecycline to overcome drug resistance in the treatment of chronic myeloid leukemia |
title_full | Inhibition of autophagy enhances the selective anti-cancer activity of tigecycline to overcome drug resistance in the treatment of chronic myeloid leukemia |
title_fullStr | Inhibition of autophagy enhances the selective anti-cancer activity of tigecycline to overcome drug resistance in the treatment of chronic myeloid leukemia |
title_full_unstemmed | Inhibition of autophagy enhances the selective anti-cancer activity of tigecycline to overcome drug resistance in the treatment of chronic myeloid leukemia |
title_short | Inhibition of autophagy enhances the selective anti-cancer activity of tigecycline to overcome drug resistance in the treatment of chronic myeloid leukemia |
title_sort | inhibition of autophagy enhances the selective anti-cancer activity of tigecycline to overcome drug resistance in the treatment of chronic myeloid leukemia |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5345227/ https://www.ncbi.nlm.nih.gov/pubmed/28283035 http://dx.doi.org/10.1186/s13046-017-0512-6 |
work_keys_str_mv | AT luziyuan inhibitionofautophagyenhancestheselectiveanticanceractivityoftigecyclinetoovercomedrugresistanceinthetreatmentofchronicmyeloidleukemia AT xuna inhibitionofautophagyenhancestheselectiveanticanceractivityoftigecyclinetoovercomedrugresistanceinthetreatmentofchronicmyeloidleukemia AT hebolin inhibitionofautophagyenhancestheselectiveanticanceractivityoftigecyclinetoovercomedrugresistanceinthetreatmentofchronicmyeloidleukemia AT panchengyun inhibitionofautophagyenhancestheselectiveanticanceractivityoftigecyclinetoovercomedrugresistanceinthetreatmentofchronicmyeloidleukemia AT lanyangqing inhibitionofautophagyenhancestheselectiveanticanceractivityoftigecyclinetoovercomedrugresistanceinthetreatmentofchronicmyeloidleukemia AT zhouhongsheng inhibitionofautophagyenhancestheselectiveanticanceractivityoftigecyclinetoovercomedrugresistanceinthetreatmentofchronicmyeloidleukemia AT liuxiaoli inhibitionofautophagyenhancestheselectiveanticanceractivityoftigecyclinetoovercomedrugresistanceinthetreatmentofchronicmyeloidleukemia |